2022 Rome Action Plan on Paediatric HIV & TB
Laurus Labs commits to:
240. Collaborating with regulators and clinicians to obtain data on the ease of administration of oral films in neonates and the paediatric population by 2024.
241. Expanding the oral film technology to other HIV products as well as TB and malaria.
242. Allocating resources to develop DRV and TAF containing FDCs for the paediatric use beginning Q2 2023.